The present invention provides novel Lactococcus lactis lactic acid bacterium strains having improved texturing properties and methods of using the strains for producing food products.

The present invention provides a novel Lactobacillus fermentum strain, named Lactobacillus fermentum strain V3, and its use in manufacturing a pharmaceutical composition or a food composition for regulating intestinal microflora and treating and/or preventing an inflammatory diseases and/or a cancer.

Provided herein, inter alia, are compositions of short chain fatty acid (SCFA)-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

A problem to be solved by the present invention is to provide a uremic toxin reducing agent, a total cholesterol reducing agent and a triglyceride reducing agent. The problem is solved by providing a uremic toxin reducing agent, a total cholesterol reducing agent and a triglyceride reducing agent, wherein each agent comprises Lactobacillus bacteria, Bifidobacterium bacteria or Bacteroides bacteria.

Disclosed are a novel Lactobacillus fermentum) E4 strain isolated from Kimchi which is a traditional Korean fermented food and a mass production method for the strain. The Lactobacillus fermentum E4 strain is verified to be a safe and useful probiotic strain through acid tolerance, bile acid tolerance, gelatin liquefaction, and urease tests. In addition, high DPPH free radical scavenging (%) associated with antioxidant activity was observed, and reduction in cytokines Iinterleukin-1β (IL-1β), Iinterleukin-8 (IL-8), Iinterleukin-6 (IL-6), and Toll-like receptor (TLR4), which are associated with an inflammatory response, was observed.

An object of the present invention is to provide a method for efficiently obtaining a lactic acid bacterium that is made to contain a large amount of double-stranded RNA; and a lactic acid bacterium having a high double-stranded RNA content obtained by the method. The object is achieved by: (1) a method for producing a double-stranded RNA-containing lactic acid bacterium, including a step of culturing a lactic acid bacterium under at least one condition of an aeration condition and a low-temperature condition lower than an optimum temperature, thereby obtaining the double-stranded RNA-containing lactic acid bacterium; (2) a double-stranded RNA-containing lactic acid bacterium, in which the content of double-stranded RNA is 2.0 times or more as compared with the content of double-stranded RNA when a bacterium of the same strain is cultured for the same culture time under an optimum temperature and non-aeration condition; or the like.

Disclosed herein is an isolated strain of Lactobacillus amylovorus LAM1345, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33510. Also disclosed herein are a composition including the isolated strain of Lactobacillus amylovorus LAM1345 for reducing trimethylamine (TMA) and/or trimethylamine-n-oxide (TMAO) levels, and use of the isolated strain of Lactobacillus amylovorus LAM1345 for treating a disease associated with at least an elevated one of TMA and TMAO levels in a subject.

Disclosed herein is an isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33617. Also disclosed herein are a composition including the isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, and use of the isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557 for alleviating an inflammation-related disorder.

Disclosed herein are compositions including cells of defined sets of microbial species (for example, 3, 16, 18, 19, 21, or 22 microbial species). Also disclosed are methods of using the microbial compositions that include contacting soil, plants, plant parts, or seeds with the composition. The microbial compositions are also used in methods of degrading biological materials, such as chitin-containing biological materials.

The present invention relates to a novel strain of Lactobacillus fermentum LM1016 deposited with the Korean Culture Center of Microorganisms under accession number KCCM12468P. The novel strain of the present invention has an effect of treating or preventing cardiovascular diseases, obesity, fatty liver or diabetes mellitus.

The present invention relates to a composition comprising the strain, and the composition may be used in a pharmaceutical product, a health functional food, a dairy product, a fermented product, a food additive and an animal feed and the like.